Skip to content
MedsAcross

Medicine

Darifenacin 15 mg extended-release tablet

Darifenacin · Oral
Available on requestPrescription onlyUS FDAGeneric name

Darifenacin 15 mg extended-release tablet is a generic prescription medicine for oral use, made by 7 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 20° to 25°C (68° to 77° F). Protect from light.

Key facts

Active ingredient (INN)
Darifenacin
Brand
Sold under the generic name
Strength
15 mg
Dosage form
Extended-release tablet
Route
Oral
Packs
8 tablets, 30 tablets, 90 tablets and 21 more
Manufacturers
Alembic PharmaceuticalsIndiaAurobindo PharmaIndiaCiplaIndiaMacleods PharmaceuticalsIndiaTorrent PharmaceuticalsIndiaRising Pharma HoldingsBryant Ranch Prepack
Origin register
US FDA, United States
Storage
Store at 20° to 25°C (68° to 77° F). Protect from light.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
G04BD10 Darifenacin
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
1 September 2016
Identifiers
RxCUI 485421, 485423DailyMed set ID 28ed5b58-46dd-4140-a877-4b422f780a94, 6e8470d1-c3e6-4644-b70a-aa47ddf79676, da7c2732-232c-4e71-92d9-577ef8617f56 +5NDC 65862-862, 69097-432, 46708-224 +5Application ANDA206743, ANDA207664, ANDA207681 +2

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
8 tablet, extended release in 1 blister pack46708-224-08Alembic PharmaceuticalsIndia12 December 2017
30 tablet, extended release in 1 bottle46708-224-30Alembic PharmaceuticalsIndia12 December 2017
90 tablet, extended release in 1 bottle46708-224-90Alembic PharmaceuticalsIndia12 December 2017
1000 tablet, extended release in 1 bottle46708-224-91Alembic PharmaceuticalsIndia12 December 2017
8 tablet, extended release in 1 blister pack62332-224-08Alembic PharmaceuticalsIndia12 December 2017
30 tablet, extended release in 1 bottle62332-224-30Alembic PharmaceuticalsIndia12 December 2017
90 tablet, extended release in 1 bottle62332-224-90Alembic PharmaceuticalsIndia12 December 2017
1000 tablet, extended release in 1 bottle62332-224-91Alembic PharmaceuticalsIndia12 December 2017
500 tablet, film coated, extended release in 1 bottle65862-862-05Aurobindo PharmaIndia19 September 2016
30 tablet, film coated, extended release in 1 bottle65862-862-30Aurobindo PharmaIndia19 September 2016
90 tablet, film coated, extended release in 1 bottle65862-862-90Aurobindo PharmaIndia19 September 2016
1000 tablet, film coated, extended release in 1 bottle65862-862-99Aurobindo PharmaIndia19 September 2016
30 tablet, extended release in 1 bottle69097-432-02CiplaIndia1 September 2016
90 tablet, extended release in 1 bottle69097-432-05CiplaIndia1 September 2016
1000 tablet, extended release in 1 bottle69097-432-15CiplaIndia1 September 2016
30 tablet, extended release in 1 bottle33342-277-07Macleods PharmaceuticalsIndia29 July 2017
90 tablet, extended release in 1 bottle33342-277-10Macleods PharmaceuticalsIndia29 July 2017
10 blister pack in 1 carton / 10 tablet, extended release in 1 blister pack33342-277-12Macleods PharmaceuticalsIndia29 July 2017
500 tablet, extended release in 1 bottle13668-203-05Torrent PharmaceuticalsIndia18 November 2016
30 tablet, extended release in 1 bottle13668-203-30Torrent PharmaceuticalsIndia18 November 2016
90 tablet, extended release in 1 bottle13668-203-90Torrent PharmaceuticalsIndia18 November 2016
30 tablet, film coated, extended release in 1 bottle16571-768-03Rising Pharma Holdings19 September 2016
90 tablet, film coated, extended release in 1 bottle16571-768-09Rising Pharma Holdings19 September 2016
30 tablet, extended release in 1 bottle72162-2571-3Bryant Ranch Prepack17 November 2025

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 22 December 2004Drugs@FDA
EU (EMA)AuthorisedEMA medicines data
India (CDSCO)Not yet confirmed against CDSCO approval lists—
AustriaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BelgiumRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BulgariaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CroatiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CyprusRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CzechiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
DenmarkRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
EstoniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FinlandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FranceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GermanyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GreeceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
HungaryRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IcelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IrelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
ItalyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LatviaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LiechtensteinRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LithuaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LuxembourgRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
MaltaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NetherlandsRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NorwayRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PolandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PortugalRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
RomaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SlovakiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SloveniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SpainRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SwedenRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Other strengths and forms of Darifenacin

Clinical summary

Darifenacin is a cholinergic muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. It is available as extended-release tablets for oral use. MedsAcross supplies Darifenacin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Darifenacin

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Darifenacin 15 mg extended-release tablet for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.